As with many early-phase studies with other PI3K inhibitors in advanced solid tumors, no association was identified between the extent of tumor shrinkage or best overall response, as per investigator assessment, and the tumor molecular alterations analyzed. The gene discussed is PIK3CA; the disease is neoplasm.